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Expression of cyclooxygenase-2 and
peroxisome proliferator-activated
receptor gamma during malignant
melanoma progression
Background: Cancer chemoprevention using nonsteroidal anti-
inflammatory drugs is frequently attributed to cyclooxygenase-2
(COX-2) inhibition, although recent studies suggest that peroxisome
proliferator-activated receptor gamma (PPARg) may also be involved.
While surgical excision remains the treatment mainstay for localized
malignant melanoma, certain high-risk patients may benefit from
adjunctive chemotherapy. In this study, we compared COX-2 and
PPARg immunohistological staining in benign nevi, primary
melanomas and metastatic melanomas to help predict the effectiveness
of compounds targeting these markers.
Methods: COX-2 and PPARg immunohistological staining was
performed and reviewed in 99 melanocytic lesions, including 38
benign nevi, 32 primary melanomas and 29 metastatic melanomas.
Results: There was a significant increase in both COX-2 and PPARg
immunostaining in melanomas compared with benign nevi. Metastatic
melanomas were more likely to have a higher number of PPARg-
immunopositive cells. They were also more likely to express COX-2
than primary melanomas. Neither COX-2 nor PPARg expression was
associated with a specific pathologic subtype.
Conclusions: COX-2 and PPARg may help modulate the
progression of melanocytic precursor lesions to disseminated malignant
melanoma. As such, they may serve as candidate substrates for
targeted cancer therapies and may be particularly useful as adjuncts to
surgery.
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Nonsteroidal anti-inflammatory drugs (NSAIDs)
have been shown to be beneficial in the prevention
of colorectal and other types of cancer in humans and
murine models.1,2 This chemopreventive effect is
most frequently attributed to cyclooxygenase (COX)
inhibition. Expression of theCOX-2 isoformhas been
particularly well studied and is known to be rapidly
induced by growth factors and tumor promoters.
Overexpression of COX-2 has been reported in
premalignant and malignant lesions derived from
a broad spectrum of tissues, including lung, breast,
prostate, bladder and the gastrointestinal
tract.3 Deletion of COX-2 in cancer-prone mice
suppresses tumor formation,4 and selective COX-2
inhibitors have been shown to provide effective
chemoprevention in humans and animal models of
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carcinogenesis.5,6 These observations suggest that
overexpression of COX-2 is an early event in
tumorigenesis and may play a role in the progression
of precursor lesions to malignant neoplasms. As such,
COX-2 may be a suitable candidate molecule for
targeted cancer therapies.
Peroxisome proliferator-activated receptor gamma
(PPARg) is a transcription factor belonging to the
nuclear receptor superfamily.7,8 It appears to play
a role in tumorigenesis, although the exact nature of
that role has yet to be defined. A number of studies
have shown that PPARg is expressed in several types
of human cancers but not in the normal tissues from
which these cancers are derived.9 PPARg agonists
have been shown to promote tumorigenesis in cancer-
pronemice;10–12 however, the same agonists have also
induced differentiation and slowed the growth of hu-
man tumor xenografts in other murine models.13–17
Studies of PPARg and COX-2 expression in
human skin have yielded mixed results. Immunohis-
tochemical analyses of COX-2 expression in benign
nevi and malignant melanomas generally showed an
increase in COX-2 expression with cancer pro-
gression.18–20 Similar studies of PPARg expression
did not detect a correlation with tumor progression
but did suggest that an association with COX-2might
exist.21,22 Interestingly, PPARg agonists did not re-
duce skin tumor formation in two well-characterized
models ofmurine skin carcinogenesis23 but did inhibit
the growth of human melanoma cell lines in vitro.24,25
In an effort to clarify whether PPARg and COX-2
are suitable molecular markers of melanoma pro-
gression, we studied their expression in benign nevi
and primary and metastatic melanomas using immu-
nohistochemistry. The data show a progressive
increase in COX-2 expression during the malignant
progression of melanocytic tumors. Similarly, mela-
nomas, but not benign melanocytic lesions, show
increased PPARg expression. To our knowledge, the
data contained herein represent the first immunohis-
tochemistry study to correlate PPARg expression with
progression of malignant melanoma.
Methods
Histopathological specimens were selected from the
files of the Department of Pathology at Northwestern
University, Chicago, IL, USA. Each case was in-
dependently reviewed by two pathologists (L. K. D
and J. A. R), and a consensus was obtained for any
discrepant cases.
Immunohistochemical analysis for COX-2 and
PPARg was performed on 38 benign nevi (20
compound, 16 intradermal and 2 junctional), 32
primary melanomas (15 superficial spreading mela-
nomas, 13 nodular melanomas, 2 lentigo maligna
melanomas and 2 in situ melanomas) and 29
metastatic melanomas. In six cases, primary and
metastatic melanomas were obtained from the same
patient. Routine hematoxylin and eosin-stained
sections were performed for histopathological
evaluation.
Formalin-fixed, paraffin-embedded slides were
stained using monoclonal antibodies against PPARg
(dilution 1 : 100; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or COX-2 (catalog number 160112;
dilution 1 : 100; Cayman Chemical, Ann Arbor, MI,
USA) and a standard avidin-biotin-peroxidase com-
plex (ABC) immunoperoxidase procedure. Nuclear
staining for PPARgwas classified into four grades on
a scale of 0–3 based on the percentage of positive cells
as follows: a score of 0 was given to specimens with 0%
nuclear staining, a score of 11was given to specimens
with 1–9%nuclear staining, a score of 21was given to
specimens with 10–50% nuclear staining and a score
of 31 was given to specimens with greater than 50%
nuclear staining. COX-2 staining was scored as either
weak or strong based on the intensity of cytoplasmic
staining.
Fisher’s exact test was used to determine statistical
significance. The chi-square test was used to deter-
mine independence. A p-value of , 0.05 was
considered statistically significant.
Results
COX-2 expression increases with malignant progression of
melanocytic lesions
Virtually all the melanocytic lesions studied showed
some level of COX-2 expression. A cytoplasmic
pattern of staining was observed (Fig. 1). As a signifi-
cant number of cases showed a faint background
blush, we interpreted COX-2 staining as either strong
or weak instead of as a percentage of immunopositive
cells. Specimens designated as strong showed intense
and crisp cytoplasmic staining. Strong expression of
COX-2was seen in 33% (33/99) of all lesions studied.
The percentage of specimens with strong expression
of COX-2was 3% (1/38) in benign nevi, 38% (12/32)
in primarymelanomas and 69% (20/29) inmetastatic
melanomas (Fig. 2 and Table 1). Fisher’s exact test
showed that these differences were statistically sig-
nificant when comparing benign nevi and primary
melanomas (p ¼ 0.0003) as well as primary and
metastatic melanomas (p , 0.0001, Table 2). These
data show a progressive increase in COX-2 expres-
sion during the malignant progression of melanocytic
tumors.
We then compared COX-2 expression in various
melanoma subtypes. Thirty-eight percent (5/13) of
nodular melanomas, 40% (6/15) of superficial
spreading melanomas and 50% (1/2) of lentigo
maligna melanomas exhibited strong COX-2 expres-
sion. There was no statistically significant association
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between increased levels of COX-2 and melanoma
subtype using Fisher’s exact test. Of note, we observed
enhanced COX-2 expression in the periphery of two
nodular melanomas (40%, 2/5), consistent with
a previous study.19
In our study, of the six individuals who had both
primary and metastatic melanomas, only two showed
strong COX-2 staining of their primary melanomas.
These results suggest that strongCOX-2 expression in
a primary melanoma is not a prognosticator of future
metastatic disease, although it is probable that our
study was not adequately powered to detect a true
difference in this subgroup.
PPARg is expressed at high levels in primary and metastatic
melanomas
Of the 99 samples studied, 22 (22%) showed
immunoreactivity against PPARg (. 10% immuno-
positive keratinocytes). Specifically, 3% (1/38) benign
nevi, 28% (9/32) primary melanomas and 41% (12/
29) metastatic melanomas expressed PPARg
(Table 1). A nuclear staining pattern was predomi-
nantly seen (Fig. 3), with cytoplasmic staining of
PPARg noted in only one metastatic melanoma
specimen. Fisher’s exact test (Table 2) showed that
these differences were statistically significant when
comparing benign nevi and primary melanomas
(p ¼ 0.004) and even more significant when compar-
ing benign nevi and metastatic melanomas (p ,
0.0001). While there appeared to be a trend toward
increased PPARg immunoreactivity in metastatic
melanomas compared with primary melanomas, this
relationship did not achieve statistical significance
(p ¼ 0.30). However, it is important to note that
. 50% nuclear staining was only seen in metastatic
melanomas (14%, 4/29, Table 3). Overall, the data
show that increased PPARg expression occurs in
melanomas but not in benign melanocytic lesions.
When we compared PPARg expression in various
melanoma subtypes, 31% (4/13) of nodular melano-
mas, 27% (4/15) of superficial spreading melanomas
and 50% (1/2) of lentigo maligna melanomas
exhibited PPARg immunoreactivity. These results
Fig. 2. Frequency of strong cyclooxygenase-2 expression in benign
nevi and malignant melanomas.
Fig. 1. Cyclooxygenase-2 expression in rep-
resentative primary (B) and metastatic (D)
melanomas by immunohistochemistry.
Hematoxylin and eosin-stained primary and
metastatic melanomas are shown in A and C,
respectively.








COX-2 1/38 (3) 12/32 (38) 20/29 (69)
PPARg 1/38 (3) 9/32 (28) 12/29 (41)
COX-2, cyclooxygenase-2; PPARg, peroxisome proliferator-activated
receptor gamma.
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showed no statistically significant association between
increased expression of PPARg and melanoma sub-
type using Fisher’s exact test.
In our study, of the six individuals who had both
primary and metastatic melanomas, only two had
primary melanomas that expressed PPARg. These
results suggest that PPARg expression in a primary
melanoma is not a prognosticator of future metastatic
disease, although we cannot rule it out completely
because of our limited sample size.
Discussion
Identifying molecular markers of cancer progression
is critical for sustaining the current focus on targeted
cancer therapies and rational drug design. An early
intervention capable of interrupting or reversing
disease progression would be particularly useful in
malignant melanoma, where the current standards of
care for metastatic disease have not resulted in
a significant survival benefit. Targeted therapies
could also be used as an adjunct to surgical excision
in patients with localized disease who are at high risk
of developing future metastases. To our knowledge,
this is the first study to report increased expression of
PPARg in human malignant melanoma. This finding
may explain why melanoma cell lines appear
susceptible to the antiproliferative effects of selective
PPARg ligands, such as thiazolidinediones.21,25
In this study, we show that PPARg is expressed in
a significant proportion of primary and metastatic
melanomas but rarely expressed in benign nevi.
Furthermore,. 50% nuclear staining was only seen
inmetastaticmelanomas, suggesting that PPARgmay
have a role in the modulation of tumor invasion. We
considered the possibility that strong expression of
PPARg in a primary melanoma might predict future
metastases. However, our study was not adequately
powered to perform this analysis. It is nonetheless
interesting to note that thiazolidinediones were
recently shown to inhibit cell migration and invasion
in human breast and pancreatic cell lines.26,27 Our
data suggest that similar results may be seen in
melanoma as well.
There are differing reports on the cellular locali-
zation of PPARg in the skin. Some studies have
observed a granular cytoplasmic pattern, while others
have noted nuclear staining.21,22 Our results are
consistent with those obtained by others who used the
same PPARg antibody, suggesting that reagent
selection may influence apparent localization. It is
also possible that the discrepancy between the data
described in Nijsten et al.22 and those described
herein is because of tumor-specific differences in
PPARg localization.
Increased expression of PPARg has been reported
in a wide range of human cancers. In melanoma cell
lines, PPARg agonists appear to suppress cellular
Table 2. p-Values of comparisons between melanocytic skin lesions for
PPARg immunoreactivity and strong COX-2 expression
Comparisons COX-2 PPARg†
Benign nevi vs. primary melanomas 0.0003 0.004
Benign nevi vs. metastatic melanomas , 0.0001 , 0.0001
Benign nevi vs. all melanomas , 0.0001 , 0.0001
Primary melanoma vs. metastatic melanomas , 0.0001 0.30
COX-2, cyclooxygenase-2; PPARg, peroxisome proliferator-activated
receptor gamma.
Intense cytoplasmic immunostaining.
†. 10% immunopositive keratinocytes.
Fig. 3. Peroxisome proliferator-activated
receptor gamma expression in a representa-
tive benign nevus (B) and metastatic mela-
noma (D) by immunohistochemistry. Of note,
the sebaceous gland in B serves as an internal
positive control. A hematoxylin and eosin-
stained benign nevus and a metastatic mel-
anoma are shown in A and C, respectively.
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proliferation and induce differentiation.21,24,25,28
However, inhibition of PPARg has produced similar
results in other cancer types, including oral squamous
cell carcinomas and hepatocellular carcinomas.29,30
We are not certain why this discrepancy occurs, but it
may be the result of off-target effects of PPARg ligands
or inherent differences between cell lines.
Strong COX-2 expression was observed in both
primary and metastatic melanomas but rarely in
benign nevi. Of note, we found that metastatic
melanomas were significantly more likely to have
strong COX-2 expression than primary melanomas.
Our results are consistent with previous studies,19,20
although we further extend the findings of Kuzbicki
et al. to include distant cutaneousmetastases as well as
lymph node metastases. The data also raise the
possibility that COX-2 promotes melanoma cell
invasiveness. Our preliminary analysis did not detect
a correlation between strong COX-2 expression in
a primary melanoma and the presence of metastatic
disease, but we recognize that the small sample size
makes it difficult to rule out a type II error.
Pharmacologic inhibition of COX-2 in melanoma
cell lines has not consistently reduced prostaglandin
E2 production or tumor cell invasiveness.19,31 It is
interesting to speculate whether this is related to off-
target effects of NSAIDs, as a COX-independent
mechanismof tumor suppression by these compounds
has been shown.32–34 Additional studies to clarify the
role of COX-2 inmelanoma progression and invasion
seem to be warranted.
Studies on colorectal cancer have suggested that
COX-2 and PPARg may have opposing effects on
tumorigenesis.35 More recently, an immunohisto-
chemical study showed that COX-2-positive squa-
mous cell carcinomas and actinic keratoses weremore
likely to express PPARg or its isoform, PPARb.22 As
such, we expected to see a correlation between COX-
2 and PPARg expression in our study. A chi-square
test for independence surprisingly did not show
a relationship between COX-2 and PPARg. While
we cannot say for certain why this discrepancy
occurred, it is possible that cancer-specific differences
may be involved.
Our study examines the expression patterns of
PPARg andCOX-2 inmelanocytic lesions of the skin.
The data suggest that both proteins play a role in the
development and biological behavior of melanomas.
More importantly, increased expression of these
markers in melanoma may enable us to tailor
treatment to selectively target malignant cells. The
prothrombotic and gastrointestinal complications of
COX-2 inhibitors have raised concerns about their
long-term safety, although these risks may be out-
weighed by a potential benefit in survival in high-risk,
disseminated or unresectable disease. Our data
showing increased PPARg expression in primary
and metastatic melanomas also provide an explana-
tion for the observed efficacy of thiazolidinediones in
melanoma cell lines. As such, drugs that target
COX-2 or PPARg, particularly those with favorable
safety profiles, may be effective adjuncts in the
treatment of melanoma.
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